Markets:

Overview

News

Currencies

International

Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

16.79 -0.25 (-1.50%)

Streaming Delayed Price Updated: 11:21 AM EDT, Jun 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 03, 2022

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics to Present at Investor Conferences in November

November 02, 2022

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

October 31, 2022

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress

October 11, 2022

From Dyne Therapeutics, Inc.

Via GlobeNewswire

Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories" ↗

July 20, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 04, 2022

On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap...

Via Benzinga

Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday ↗

September 27, 2022

U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Dyne Therapeutics: Q2 Earnings Insights ↗

August 04, 2022

Dyne Therapeutics (NASDAQ:DYN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew ↗

July 12, 2022

Via Benzinga

Dyne's Shares Gain After FDA Removed Clinical Hold On Muscular Disease Study ↗

July 05, 2022

Dyne Therapeutics (NASDAQ: DYN) announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared its Investigational New Drug (IND) application to initiate a clinical...

Via Benzinga

What's Going On With Dyne Therapeutics Shares Today? ↗

July 05, 2022

Dyne Therapeutics Inc (NASDAQ: DYN) shares are trading lower by 5.42% to $6.81 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 05, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗

July 12, 2022

Upgrades

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday ↗

July 06, 2022

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.

Via Benzinga

selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform

March 17, 2022

SAN RAMON, CA / ACCESSWIRE / March 17, 2022 / Grid Dynamics Holdings, Inc. (NASDAQ:DYN) (Grid Dynamics), a leader in enterprise-level digital engineering services and solutions, today announced it has...

From Grid Dynamics

Via AccessWire

Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session ↗

July 05, 2022

Gainers Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter.

Via Benzinga

Mid-Afternoon Market Update: Dow Dips 500 Points; NeuroMetrix Shares Spike Higher ↗

January 18, 2022

Toward the end of trading Tuesday, the Dow traded down 1.4% to 35,410 while the NASDAQ fell 2.12% to 14,577.79. The S&P also fell, dropping, 1.60% to 4,588.10. The U.S. has...

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

June 02, 2022

During the Thursday's session, 100 stocks hit new 52-week lows.

Via Benzinga

Mid-Day Market Update: Nasdaq Tumbles 250 Points; Activision Blizzard Shares Jump ↗

January 18, 2022

Midway through trading Tuesday, the Dow traded down 1.58% to 35,343.17 while the NASDAQ fell 1.70% to 14,640.00. The S&P also fell, dropping, 1.57% to 4,589.66. The U.S. has...

Via Benzinga

65 Biggest Movers From Yesterday ↗

January 19, 2022

Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and...

Via Benzinga

34 Stocks Moving In Tuesday's Mid-Day Session ↗

January 18, 2022

Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares gained 37.2% to $6.75 after the company eeceived FDA Breakthrough Device Designation for the treatment of chronic chemo induced...

Via Benzinga

FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program ↗

January 18, 2022

The FDA has placed a clinical hold on Dyne Therapeutics Inc's (NASDAQ: DYN) investigational New Drug (IND) application to initiate a clinical trial of DYNE...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 12, 2022

On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a...

Via Benzinga

Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program ↗

October 01, 2021

Dyne Therapeutics Inc (NASDAQ: DYN) has announced new data presented today during the 2021 Muscle Study Group Annual Scientific Meeting for its Duchenne muscular...

Via Benzinga

The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout ↗

June 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,...

Via Benzinga

Stocks Hitting New 52-Week Lows Today ↗

January 03, 2022

On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was...

Via Benzinga

Dyne Therapeutics' Myotonic Dystrophy Gene Therapy Shows Encouraging Action In Animal Studies ↗

May 14, 2021

Dyne Therapeutics Inc (NASDAQ: DYN) has announced new preclinical data from its myotonic dystrophy type 1 (DM1) program, including results demonstrating...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.